THe flight of thunderbolts/ por 223048 Schonland, Basil Ferdinand Jamieson

Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients wit... por Annemarie Glöckner, Stefan Schönland, Hermann Einsele, Nicolaus Kröger

Enlace del recurso

Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a “graft-versus-plasma cell-dyscrasia effect” por Stefan O. Schonland, Nicolaus Kröger, Christine Wolschke, Peter Dreger, Anthony D. Ho, Ute Hegenbart

Enlace del recurso

Bone involvement in patients with systemic AL amyloidosis mimics lytic myeloma bone disease por Stefan O. Schonland, Jochen Hansmann, Gunnhild Mechtersheimer, Hartmut Goldschmidt, Anthony D. Ho, Ute Hegenbart

Enlace del recurso

CD4+CD25highCD127low Regulatory T Cells in Peripheral Blood Are Not an Independent Factor for Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation por Jolanta B. Perz, Selma Gürel, Stefan O. Schonland, Ute Hegenbart, Anthony D. Ho, Peter Dreger

Enlace del recurso

Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation por Jennifer Mosebach, Sofia Shah, Stefan Delorme, Thomas Hielscher, Hartmut Goldschmidt, Heinz-Peter Schlemmer, Stefan Schönland, Ute Hegenbart, Jens Hillengass

Enlace del recurso

Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis por Nora Liebers, Stefan O. Schönland, Claudius Speer, Dominic Edelmann, Paul Schnitzler, Hans-Georg Kräusslich, Carsten Mueller-Tidow, Ute Hegenbart, Sascha Dietrich

Enlace del recurso

Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wi... por Martin Granzow, Ute Hegenbart, Katrin Hinderhofer, Dirk Hose, Anja Seckinger, Tilmann Bochtler, Kari Hemminki, Hartmut Goldschmidt, Stefan O. Schönland, Anna Jauch

Enlace del recurso

Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis por Nisha Arenja, Florian Andre, Johannes H. Riffel, Fabian aus dem Siepen, Ute Hegenbart, Stefan Schönland, Arnt V. Kristen, Hugo A. Katus, Sebastian J. Buss

Enlace del recurso

Prognosis of light chain amyloidosis: a multivariable analysis for survival prediction in patients with cardiac involvement proven by endomyocardial biopsy por Sebastian Greiner, Matthias Aurich, Hugo A Katus, Derliz Mereles, Norbert Frey, Fabian aus dem Siepen, Julian Bucur, Johannes A Vey, Ute Hegenbart, Stefan Schönland

Enlace del recurso

Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis por Tilmann Bochtler, Ute Hegenbart, Christiane Heiss, Axel Benner, Friedrich Cremer, Martin Volkmann, Jochen Ludwig, Jolanta B. Perz, Anthony D. Ho, Hartmut Goldschmidt, Stefan O. Schonland

Enlace del recurso

P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK por E. Kastritis, G. Palladini, M. A. Dimopoulos, A. Jaccard, G. Merlini, F. Theodorakakou, D. Fotiou, M. C. Minnema, A. Wechalekar, S. Gkolfinopoulos, K. Manousou, P. Sonneveld, S. Schönland

Enlace del recurso

P899: HOVON 104; LONG TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS por Monique Minnema, Kazem Nasserinejad, Ute Hegenbart, Paula Ypma, Ka Lung Wu, Marie José Kersten, Sandra Croockewit, Esther de Waal, Sonja Zweegman, Lidwien Tick, Annemiek Broijl, Stefan Schönland

Enlace del recurso

Light chain mutations contribute to defining the fibril morphology in systemic AL amyloidosis por Sara Karimi-Farsijani, Peter Benedikt Pfeiffer, Sambhasan Banerjee, Julian Baur, Lukas Kuhn, Niklas Kupfer, Ute Hegenbart, Stefan O. Schönland, Sebastian Wiese, Christian Haupt, Matthias Schmidt, Marcus Fändrich

Enlace del recurso

Cryo-EM structure of a lysozyme-derived amyloid fibril from hereditary amyloidosis por Sara Karimi-Farsijani, Kartikay Sharma, Marijana Ugrina, Lukas Kuhn, Peter Benedikt Pfeiffer, Christian Haupt, Sebastian Wiese, Ute Hegenbart, Stefan O. Schönland, Nadine Schwierz, Matthias Schmidt, Marcus Fändrich

Enlace del recurso

Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia por Tobias Dittrich, Axel Benner, Christoph Kimmich, Fabian aus dem Siepen, Kaya Veelken, Arnt V. Kristen, Tilmann Bochtler, Hugo A. Katus, Carsten Müller-Tidow, Ute Hegenbart, Stefan O. Schönland

Enlace del recurso

S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK por Efstathios Kastritis, Giovanni Palladini, Meletios A. Dimopoulos, Arnaud Jaccard, Giampaolo Merlini, Foteini Theodorakakou, Despina Fotiou, Monique C. Minnema Minnema, Ashutosh Wechalekar, Elena Papachristou, Kyriaki Manousou, Pieter Sonneveld, Stefan Schönland

Enlace del recurso

Regional differences in prognostic value of cardiac valve plane displacement in systemic light-chain amyloidosis por Marco M. Ochs, Thomas Fritz, Nisha Arenja, Johannes Riffel, Florian Andre, Derliz Mereles, Fabian aus dem Siepen, Ute Hegenbart, Stefan Schönland, Hugo A. Katus, Matthias G. W. Friedrich, Sebastian J. Buss

Enlace del recurso

Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival por Sara Oubari, Ute Hegenbart, Renate Schoder, Maximilian Steinhardt, Maria Papathanasiou, Tienush Rassaf, Andreas Thimm, Tim Hagenacker, Eyad Naser, Ulrich Duhrsen, Hans C. Reinhardt, Martin Kortum, Hermine Agis, Stefan Schonland, Alexander Carpinteiro

Enlace del recurso

HOVON 104, long‐term follow‐up of bortezomib‐dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients por Monique C. Minnema, Kazem Nasserinejad, Ute Hegenbart, Paula F. Ypma, Ka Lung Wu, Marie Jose Kersten, Sandra Croockewit, Sonja Zweegman, Lidwine Tick, Annemiek Broijl, Harry Koene, Gerard M. J. Bos, Pieter Sonneveld, Stefan O. Schönland

Enlace del recurso